Bayesian Capital Management’s Amedisys AMED Stock Holding History

Bayesian Capital Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,000	Closed	-$1.18M	–	774
2023 Q1	$1.18M	Buy	+16,000	New	+$1.38M	0.15%	212
2019 Q2	–	Sell	-5,700	Closed	-$703K	–	497
2019 Q1	$703K	Sell	5,700 -16,088	-74%	-$2.02M	0.13%	213
2018 Q4	$2.55M	Buy	21,788 +8,024	+58%	+$946K	0.52%	35
2018 Q3	$1.72M	Buy	13,764 +9,100	+195%	+$1M	0.28%	86
2018 Q2	$399K	Buy	+4,664	New	+$342K	0.09%	324
2018 Q1	–	Sell	-6,185	Closed	-$326K	–	565
2017 Q4	$326K	Buy	+6,185	New	+$326K	0.07%	402
2017 Q2	–	Sell	-5,361	Closed	-$274K	–	414
2017 Q1	$274K	Buy	+5,361	New	+$256K	0.13%	276

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Bayesian Capital Management's AMED Position: Q2 2023 in Review

Bayesian Capital Management sold out of Amedisys (AMED) in Q2 2023, closing a stake of 16,000 shares — an estimated $1.18M sold.

Bayesian Capital Management first reported a position in AMED in Q1 2017 and held it in 7 quarters. The position peaked at $2.55M in Q4 2018. 301 funds tracked by Wall St. Rank hold AMED as of Q2 2023.

Bayesian Capital Management reported no remaining Amedisys position as of Q2 2023 after selling out during the quarter.
Bayesian Capital Management sold 16,000 Amedisys shares in Q2 2023, an estimated $1.18M.
Bayesian Capital Management first reported a position in Amedisys in Q1 2017 and held it in 7 quarters.
Bayesian Capital Management's Amedisys position peaked at $2.55M in Q4 2018.
301 funds tracked by Wall St. Rank held Amedisys as of Q2 2023.

Based on Bayesian Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.